Skip to main content
Xiaonan Lu on Muck Rack

Xiaonan Lu

Montreal
As seen in: Nature, Wiley Online Library, Frontiers, MDPI, ACS Publications, Royal Society of Chemistry, BioRxiv, Chemistry World, World Oil
Professor, Tier-1 Canada Research Chair in Food Safety
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiaonan

Contact Xiaonan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Leveraging Inequality-Constrained Data for Enhanced Liquidus Temperature Prediction in Nuclear Waste Glass Melts

|
By Xiaonan Lu, José Marcial, Erick Garcia-Morado
| Wiley Online Library Verified
, , , , and , “Leveraging Inequality-Constrained Data for Enhanced Liquidus Temperature Prediction in Nuclear Waste Glass Melts.” International Journal of Applied Ceramic Technology23, no. 4 (2026): e70243. https://doi.org/10.1111/ijac.70243 Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The implementation code for this study is available through the following GitHub repository: https://github.com/Morado-PhD/L1-norm.
Open in Who Shared Issue with article?

Banxia xiexin decoction and its bioactive metabolites: multi-targeted mechanisms for suppressing gastric cancer progression, reversing chemoresistance, and remodeling the tumor microenvironment

|
By Donghan Xu, Ziqing Lin, Lu Deng, Xiaonan Lu, Ziyi Guo, Peiyu Yan, Yehao Luo
| Frontiers
Abstract Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, primarily due to late diagnosis and limited benefit from surgery alone. Although chemotherapy, targeted agents, and immunotherapy have improved outcomes for selected patients, their clinical benefits are often limited by significant toxicity, acquired resistance, and the pronounced molecular heterogeneity of GC. Multi-target therapeutic approaches are therefore urgently needed.
Open in Who Shared Issue with article?

Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study

|
By Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia
| Frontiers
Abstract Background: The optimal second-line therapy for advanced gastric/gastroesophageal junction cancer (GC/GEJC) following progression on first-line immuno-chemotherapy remains undefined. This study aimed to compare the efficacy and safety of continuing an immune checkpoint inhibitor beyond progression (CIBP) versus switching to a non-ICI regimen (non-CIBP).
Open in Who Shared Issue with article?
See all 28 articles